Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.
Cervical Intraepithelial Neoplasia|Cervical Cancer|Condylomata Acuminata
BIOLOGICAL: Nonavalent HPV vaccine|BIOLOGICAL: Bivalent HPV vaccine
Non-inferiority of anti-HPV 16 and 18 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody) in the PPS-I set, Detect the level of anti-HPV 16 and 18 specific neutralizing antibodies at one month after the third dose to determine whether nine-valent HPV vaccine is non-inferior to the control bivalent HPV vaccine, Specific neutralizing antibodies at 7 months after first dose|Persistent infection of HPV31, 33, 45, 52 and 58 (over 12 months) (Combined analysis of the 5 types) in the mITT-PI set, To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions related to HPV 31, 33, 45, 52 or 58 (Combined analysis of the 5 types) in the mITT-E when the first two endpoints are satisfied, To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose
Efficacy1: Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types) and genital warts related to HPV 6, 11 (Combined analysis of each type), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy2: Incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types) and genital warts related to HPV 6, 11 (Combined analysis of each type), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy3: Incidence of Persistent infection of HPV31, 33, 45, 52 and 58 (transient infection and over 6 months) (Combined analysis of the 5 types), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy4: Incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy5: Incidence of Persistent infection of HPV31, 33, 45, 52 and 58 (over 6 months) and/or incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 31, 33, 45, 52 or 58(Combined analysis of the 5 types), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy6: Incidence of genital warts related to HPV 6, 11, To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy7: Incidence of Persistent infection of HPV31, 33, 45, 52, 58, 6 and 11 (transient infection and over 6 months and over 12 months) (Combined analysis of the 7 types), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Efficacy8: Incidence of Persistent infection of HPV31, 33, 45, 52, 58, 6 and 11 (over 6 months and over 12 months) (Independent analysis of each type), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Immunogenicity1: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7, Analysis the seroconversion and geometric mean concertration of the type specific antibodies of the 7 types., Month 7 after first vaccination|Immunogenicity2: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 18 and 30, Analysis the seroconversion and geometric mean concertration of the type specific antibodies of the 7 types., Month 18 and 30 after first vaccination|Immunogenicity3: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 42, 54, 66 and 78, Analysis the seroconversion and geometric mean concertration of the type specific antibodies of the 7 types., Month 42, 54, 66 and 78 after first vaccination|Safety1: Local and systematic adverse events/reactions occurred within 7 days after each vaccination, safety analysis, During the 7-day (Day 0-6) period following each vaccination|Safety2: Adverse events/reactions occurred within 30 days after each vaccination, safety analysis, Within 30 days (Day 0-30) after any vaccination|Safety3: Serious adverse events occurred throughout the study, safety analysis. To evaluate number of SAEs compared with the control vaccine., Up to 78 month|Safety4: Pregnancy and pregnancy outcome, safety analysis. To evaluate number of births and terminations compared with the control vaccine., Up to 78 month|Safety5: Emerging chronic diseases, safety analysis.To evaluate number of emerging chronic diseases compared with the control vaccine., Up to 78 month
Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions related to HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68 (Combined analysis of the high risk types), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Incidence of CIN1 + and/or VIN1 + and/or VaIN1 + lesions related to HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68 (Combined analysis of the high risk types), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose|Incidence of Persistent infection of HPV35, 39,51,56,59 and 68 (total infection and over 6 months and over 12 months) (Independent analysis of each type), To evaluate the efficacy of the nine-valent vaccine against this outcome compared with the control vaccine, Cumulative incidence of this endpoint events in 78 months after the first dose
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.